Document is current
Any future updates will be listed below
-
Authors
Wellmann, Irmgardt Alicia
Ayala, Luis Fernando
Rodríguez, José Javier
Guetterman, Timothy C.
Irazola, Vilma
Palacios, Eduardo
Huffman, Mark D.
Rohloff, Peter
Heisler, Michele
Ramírez-Zea, Manuel
Flood, David https://orcid.org/0000-0002-4372-7387
-
Funding
Funding for this research was provided by:
NHLBI (K23HL16127101)
Michigan Diabetes Research Center, University of Michigan
- License Information
-
More Information
Article History
Received: 12 October 2023
Accepted: 7 December 2023
First Online: 9 January 2024
Declarations
:
: This research has been approved by the Ethics Committees of the Ministry of Health of Guatemala (07–2023), INCAP (CIE-REV 124/2023), and the University of Michigan (HUM00234613). Protocol revisions will be submitted for approval at each institution’s ethics committee. Informed consent will not be obtained from patient participants receiving routine care at MOH primary care facilities as the research meets all five required criteria in the revised Common Rule. Verbal consent will be obtained by study staff from participants interviewed at the study conclusion and from stakeholders participating in the Technical Advisory Committee.
: Not applicable.
: D. F. and I. A. W. have served as consultants for the World Health Organization. M. D. H. has pending patents for heart failure polypills. George Health Enterprises Pty Ltd. (GH) and its subsidiary, George Medicines Pty Ltd., have received investment funds to develop fixed‐dose combination products, including combinations of blood pressure‐lowering drugs. GH is the social enterprise arm of The George Institute for Global Health. The other authors declare that they have no competing interests.
